The absolute neutrophil count (ANC) converts a routine CBC differential into a single number that tells you how many infection-fighting neutrophils are actually circulating in the blood. It's the key lab value used to monitor chemotherapy-induced neutropenia and gauge infection risk in oncology and hematology.

How ANC is calculated

ANC = WBC x 1000 x (%Neutrophils + %Bands) / 100. The white blood cell count (WBC) is reported in thousands per microliter (×10³/µL), so multiplying by 1000 converts it to an absolute cell count per microliter. That count is then scaled by the combined percentage of neutrophils and bands from the CBC differential.

This is the same relationship MDCalc expresses as 10 x WBC(in thousands) x (%segs + %bands) — the two forms are mathematically identical, since dividing a percentage by 100 and multiplying by 1000 is the same as multiplying by 10.

Why bands are included

Bands are an immature form of neutrophil — cells that have not yet fully matured into segmented neutrophils ("segs") but are still released from the bone marrow and still capable of fighting infection. Standard hematology convention adds the band percentage to the segmented neutrophil percentage when calculating ANC, rather than counting only fully mature segs.

This matters clinically: a differential with a high proportion of bands (a "left shift") often signals the bone marrow is responding to infection or inflammation by releasing neutrophils faster than they can fully mature.

Neutropenia severity and febrile risk

An ANC of 1,500 cells/µL or higher is considered normal. Below that, neutropenia is graded mild (1,000–1,499), moderate (500–999), or severe (below 500) — and infection risk climbs sharply as the count falls into the severe range.

The single most important clinical trigger is fever combined with an ANC below 500: febrile neutropenia. Because a severely suppressed neutrophil count can blunt the usual signs of infection, fever in this setting is treated as an oncologic emergency, prompting immediate evaluation and empiric broad-spectrum antibiotics rather than a wait-and-see approach.